EGFR ligands normally function as autocrine or paracrine activators of EGFR; however, by packaging EVs with EGFR ligands, tumours have found a mechanism to extend the functional distance these ligands can act upon and possibly to target specific cells with larger concentrations of EGFR ligands. Here, EGFR is linked to neoplasm.